02/03/2015 - 1:38pm

Afrezza, an inhaled insulin powder, is now available by prescription in U.S. retail pharmacies, Sanofi and MannKind Corp. announced. The drug is approved by the Food and Drug Administration to control high blood sugar in adults who have type 1 and type 2 diabetes.

 

02/03/2015 - 1:25pm

Diplomat Pharmacy announced Monday that it has earned the Verified Internet Pharmacy Practice Sites seal of approval from the National Association of Boards of Pharmacy.

02/03/2015 - 11:18am

Teva Pharmaceuticals on Tuesday announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in 10-mg dosage strength.

02/03/2015 - 10:08am

CVS/pharmacy's mobile app has undergone a complete transformation, with new features and an improved look and feel.

 

02/02/2015 - 9:43am

The Food and Drug Administration announced that it has expanded the approved uses of Vyvanse (lisdexamfetamine dimesylate) to treat binge-eating disorder in adults, making it the first FDA-approved medicine to treat this condition.

 

02/02/2015 - 9:18am

Mylan announced that it will acquire certain businesses from specialty women's healthcare company Famy Care Limited for $750 million, with additional contingent payments of up to $50 million. 

01/30/2015 - 1:13pm

Janssen Therapeutics on Thursday announced that the Food and Drug Administration has approved its Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets. The drug is used to treat human immunodeficiency virus in combination with other antiretovirals for treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions, according to the company.

 

01/30/2015 - 10:25am

BioPlus Specialty Pharmacy announced Thursday that URAC, the largest accrediting body for health care, has once again given BioPlus its seal of approval by accrediting it through an on-site process.

01/30/2015 - 10:21am

Diplomat Pharmacy announced Thursday that the Food and Drug Administration has approved an expanded indication of Imbruvica (ibrutinib) for the treatment of Waldenström’s macroglobulinemia (WM).